» Articles » PMID: 25503801

Metachronous Metastases from Colorectal Cancer: a Population-based Study in North-East Netherlands

Overview
Date 2014 Dec 16
PMID 25503801
Citations 77
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The main cause of death of colorectal cancer patients is metastatic disease. Approximately 20-25% of the patients present with metastases at time of diagnosis. The clinical course of patients who develop metachronous metastases, however, is less clear. The aims of this study were to describe the incidence, treatment and survival of patients with metachronous metastases from colorectal cancer and to determine risk factors for developing metachronous metastases.

Methods: From the Netherlands Cancer Registry, patients diagnosed with colorectal carcinoma in the period 2002-2003 in North-East Netherlands were selected. Patients were followed for 5 years after diagnosis of the primary tumour. Kaplan-Meier method and Cox regression analyses were used to determine predictors for developing metastases and to analyse overall survival.

Results: In total, 333 of 1743 (19%) patients developed metachronous metastases. The majority (83%) of these metastases were diagnosed within 3 years, and the most frequent site was the liver. Patients with advanced stage and patients with tumours in the descending colon or in the rectum were more likely to develop metastases. Approximately 10% of all patients underwent intentionally curative treatment for their metastases, with a 5-year survival rate of 60%. Treatment of metastases and pathologic N (pN) status were independent prognostic factors for overall survival.

Conclusions: Site and stage of the primary tumour were predictors for developing metachronous metastases. A limited number of patients with metastatic disease were treated with a curative intent. These patients had a good prognosis. Therefore, focus should be on identifying more patients who could benefit from curative treatment.

Citing Articles

Early Recurrence of Colorectal Liver Metastasis (Number ≤ 5 and Largest Diameter ≤ 3 cm) after Resection or Thermal Ablation: a Multi-center Study of Patterns, Safety, Survival and Risk Factors.

Kong Y, Huang X, Cao X, Tang F, Zhou X J Gastrointest Cancer. 2025; 56(1):77.

PMID: 40072796 DOI: 10.1007/s12029-025-01200-4.


Enhanced Lymph Node Detection in Colon Cancer Using Indocyanine Green Fluorescence: A Systematic Review of Studies from 2020 Onwards.

Negrut R, Cote A, Feder B, Bodog F, Maghiar A J Pers Med. 2025; 15(2).

PMID: 39997331 PMC: 11855940. DOI: 10.3390/jpm15020054.


Role of Adjuvant Chemotherapy After Surgical Resection of Paraaortic Lymph Node Metastasis from Colorectal Cancer-A Multicenter Retrospective Study.

Nozawa H, Ito S, Sasaki K, Murono K, Emoto S, Yokoyama Y Ann Surg Oncol. 2024; 32(4):2282-2291.

PMID: 39557718 PMC: 11882702. DOI: 10.1245/s10434-024-16537-6.


Challenges and Opportunities for Precision Surgery for Colorectal Liver Metastases.

OConnell R, Hoti E Cancers (Basel). 2024; 16(13).

PMID: 39001441 PMC: 11240734. DOI: 10.3390/cancers16132379.


Added Value of Liver MRI in Patients Eligible for Surgical Resection or Ablation of Colorectal Liver Metastases Based on CT: A Systematic Review and Meta-Analysis.

Gorgec B, Verpalen I, Sijberden J, Abu Hilal M, Bipat S, Verhoef C Ann Surg Open. 2024; 5(1):e401.

PMID: 38883954 PMC: 11175892. DOI: 10.1097/AS9.0000000000000401.


References
1.
Hugen N, van de Velde C, de Wilt J, Nagtegaal I . Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol. 2014; 25(3):651-657. PMC: 4433523. DOI: 10.1093/annonc/mdt591. View

2.
Verberne C, Wiggers T, Vermeulen K, de Jong K . Detection of recurrences during follow-up after liver surgery for colorectal metastases: both carcinoembryonic antigen (CEA) and imaging are important. Ann Surg Oncol. 2012; 20(2):457-63. DOI: 10.1245/s10434-012-2629-3. View

3.
de Jong K, Wertenbroek M . Liver resection combined with local ablation: where are the limits?. Dig Surg. 2011; 28(2):127-33. DOI: 10.1159/000323823. View

4.
Jones R, Vauthey J, Adam R, Rees M, Berry D, Jackson R . Effect of specialist decision-making on treatment strategies for colorectal liver metastases. Br J Surg. 2012; 99(9):1263-9. DOI: 10.1002/bjs.8835. View

5.
Folprecht G, Gruenberger T, Bechstein W, Raab H, Lordick F, Hartmann J . Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2009; 11(1):38-47. DOI: 10.1016/S1470-2045(09)70330-4. View